Works matching IS 01676997 AND DT 2022 AND VI 40 AND IP 2

Results: 30

Acknowledgement of Reviewers 2021.

Published in:: Investigational New Drugs, 2022, v. 40, n. 2, p. 465, doi. 10.1007/s10637-022-01240-8
Publication type:: Article

Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 349, doi. 10.1007/s10637-021-01206-2

By:

Zhou, Daobin;
Xu, Wei;
Ma, Hongbing;
Zhao, Chunting;
Hu, Yu;
Zhao, Yaozhong;
Wu, Depei;
Zhao, Xielan;
He, Yanjuan;
Yan, Jinsong;
Wang, Chunsen;
Meng, Fanyi;
Jin, Jie;
Zhang, Xiaohong;
Yu, Kang;
Hu, Jianda;
Lv, Yue

Publication type:

Article

Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 340, doi. 10.1007/s10637-021-01205-3

By:

Rong, Xuetong;
Liu, Haiyi;
Yu, Hongmei;
Zhao, Jian;
Wang, Jie;
Wang, Yusheng

Publication type:

Article

Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 274, doi. 10.1007/s10637-021-01204-4

By:

Song, Gaojie;
Shang, Chao;
Sun, Lili;
Li, Yiquan;
Zhu, Yilong;
Xiu, Zhiru;
Liu, Zirui;
Li, Yaru;
Yang, Xia;
Ge, Chenchen;
Fang, Jinbo;
Jin, Ningyi;
Li, Xiao

Publication type:

Article

Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR-TKI: HOPE-002.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 361, doi. 10.1007/s10637-021-01203-5

By:

Tamiya, Motohiro;
Fujikawa, Kei;
Suzuki, Hidekazu;
Yokoyama, Toshihide;
Uenami, Takeshi;
Tamiya, Akihiro;
Sato, Yuki;
Saito, Go;
Uchida, Junji;
Morita, Mitsunori;
Hirashima, Tomonori;
Fukuda, Yasushi;
Kanazu, Masaki;
Hosoya, Kazutaka;
Suzuki, Takuji;
Ueno, Kiyonobu;
Fujimoto, Daichi;
Kumagai, Toru;
Teramukai, Satoshi

Publication type:

Article

A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 322, doi. 10.1007/s10637-021-01202-6

By:

Maurice-Dror, Corinne;
Le Moigne, Ronan;
Vaishampayan, Ulka;
Montgomery, Robert B.;
Gordon, Michael S.;
Hong, Nan Hyung;
DiMascio, Leah;
Perabo, Frank;
Chi, Kim N.

Publication type:

Article

Boron neutron capture therapy using dodecaborated albumin conjugates with maleimide is effective in a rat glioma model.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 255, doi. 10.1007/s10637-021-01201-7

By:

Kashiwagi, Hideki;
Kawabata, Shinji;
Yoshimura, Kohei;
Fukuo, Yusuke;
Kanemitsu, Takuya;
Takeuchi, Koji;
Hiramatsu, Ryo;
Nishimura, Kai;
Kawai, Kazuki;
Takata, Takushi;
Tanaka, Hiroki;
Watanabe, Tsubasa;
Suzuki, Minoru;
Miyatake, Shin-Ichi;
Nakamura, Hiroyuki;
Wanibuchi, Masahiko

Publication type:

Article

Relevance of pharmacogenetic polymorphisms with response to docetaxel, cisplatin, and 5-fluorouracil chemotherapy in esophageal cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 420, doi. 10.1007/s10637-021-01199-y

By:

Nomura, Hisanaga;
Tsuji, Daiki;
Ueno, Shohei;
Kojima, Takashi;
Fujii, Satoshi;
Yano, Tomonori;
Daiko, Hiroyuki;
Demachi, Ken;
Itoh, Kunihiko;
Kawasaki, Toshikatsu

Publication type:

Article

Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer.

Published in:

2022

By:

Nishimura, Ari;
Ono, Akira;
Wakuda, Kazushige;
Kawabata, Takanori;
Yabe, Michitoshi;
Miyawaki, Taichi;
Miyawaki, Eriko;
Kodama, Hiroaki;
Nishioka, Naoya;
Mamesaya, Nobuaki;
Kobayashi, Haruki;
Omori, Shota;
Kenmotsu, Hirotsugu;
Naito, Tateaki;
Murakami, Haruyasu;
Harada, Hideyuki;
Takahashi, Toshiaki

Publication type:

Correction Notice

STMN1 is highly expressed and contributes to clonogenicity in acute promyelocytic leukemia cells.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 438, doi. 10.1007/s10637-021-01197-0

By:

Vicari, Hugo Passos;
Coelho-Silva, Juan Luiz;
Pereira-Martins, Diego A.;
Lucena-Araujo, Antônio Roberto;
Lima, Keli;
Lipreri da Silva, Jean Carlos;
Scheucher, Priscila Santos;
Koury, Luisa C.;
de Melo, Raul A.;
Bittencourt, Rosane;
Pagnano, Katia;
Nunes, Elenaide;
Fagundes, Evandro M.;
Kerbauy, Fabio;
de Figueiredo-Pontes, Lorena Lobo;
Costa-Lotufo, Leticia Veras;
Rego, Eduardo Magalhães;
Traina, Fabiola;
Machado-Neto, João Agostinho

Publication type:

Article

FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 245, doi. 10.1007/s10637-021-01196-1

By:

Ishikawa, Chie;
Mori, Naoki

Publication type:

Article

First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 430, doi. 10.1007/s10637-021-01195-2

By:

Igawa, Satoshi;
Fukui, Tomoya;
Kasajima, Masashi;
Ono, Taihei;
Ozawa, Takahiro;
Kakegawa, Mikiko;
Kusuhara, Seiichiro;
Sato, Takashi;
Nakahara, Yoshiro;
Hisashi, Mitsufuji;
Sasaki, Jiichiro;
Naoki, Katsuhiko

Publication type:

Article

Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study.

Published in:

2022

By:

Thein, Kyaw Z.;
Karp, Daniel D.;
Tsimberidou, Apostolia;
Gong, Jing;
Sulovic, Selma;
Shah, Jatin;
Milton, Denái R.;
Hong, David S.;
Janku, Filip;
McQuinn, Lacey;
Stephen, Bettzy A.;
Colen, Rivka;
Carter, Brett W.;
Yap, Timothy A.;
Piha‑Paul, Sarina A.;
Fu, Siqing;
Meric‑Bernstam, Funda;
Naing, Aung

Publication type:

Correction Notice

Correction to: Identification and characterization of deschloro-chlorothricin obtained from a large natural product library targeting aurora A kinase in multiple myeloma.

Published in:

2022

By:

Özenver, Nadire;
Abdelfatah, Sara;
Klinger, Anette;
Fleischer, Edmond;
Efferth, Thomas

Publication type:

Correction Notice

Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study.

Published in:

2022

By:

Thein, Kyaw Zin;
Piha-Paul, Sarina A.;
Tsimberidou, Apostolia;
Karp, Daniel D.;
Janku, Filip;
Zarifa, Abdulrazzak;
Shah, Jatin;
Milton, Denái R.;
Bean, Stacie;
McQuinn, Lacey;
Gong, Jing;
Colen, Rivka;
Carter, Brett W.;
Subbiah, Vivek;
Ogbonna, Deby C.;
Pant, Shubham;
Meric-Bernstam, Funda;
Naing, Aung

Publication type:

Correction Notice

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 403, doi. 10.1007/s10637-021-01191-6

By:

Nishimura, Ari;
Ono, Akira;
Wakuda, Kazushige;
Kawabata, Takanori;
Yabe, Michitoshi;
Miyawaki, Taichi;
Miyawaki, Eriko;
Kodama, Hiroaki;
Nishioka, Naoya;
Mamesaya, Nobuaki;
Kobayashi, Haruki;
Omori, Shota;
Kenmotsu, Hirotsugu;
Naito, Tateaki;
Murakami, Haruyasu;
Harada, Hideyuki;
Takahashi, Toshiaki

Publication type:

Article

Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 224, doi. 10.1007/s10637-021-01190-7

By:

Schnoell, Julia;
Stanisz, Isabella;
Jank, Bernhard J.;
Stanek, Victoria;
Schmid, Rainer;
Brunner, Markus;
Heiduschka, Gregor;
Kotowski, Ulana

Publication type:

Article

Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 290, doi. 10.1007/s10637-021-01188-1

By:

Thein, Kyaw Z.;
Karp, Daniel D.;
Tsimberidou, Apostolia;
Gong, Jing;
Sulovic, Selma;
Shah, Jatin;
Milton, Denái R.;
Hong, David S.;
Janku, Filip;
McQuinn, Lacey;
Stephen, Bettzy A.;
Colen, Rivka;
Carter, Brett W.;
Yap, Timothy A.;
Piha-Paul, Sarina A.;
Fu, Siqing;
Meric-Bernstam, Funda;
Naing, Aung

Publication type:

Article

Advances in glioma-associated oncogene (GLI) inhibitors for cancer therapy.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 370, doi. 10.1007/s10637-021-01187-2

By:

Zhang, Meng;
Gao, Lijuan;
Ye, Yiping;
Li, Xiaoyu

Publication type:

Article

Relapsing polychondritis after treatment with PD-1 blockade.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 389, doi. 10.1007/s10637-021-01186-3

By:

Ogimoto, Tatsuya;
Yoshida, Hironori;
Mizuta, Masanobu;
Hirai, Toyohiro

Publication type:

Article

Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 392, doi. 10.1007/s10637-021-01185-4

By:

Hayakawa, Yuka;
Tsuchiya, Kaoru;
Kurosaki, Masayuki;
Yasui, Yutaka;
Kaneko, Shun;
Tanaka, Yuki;
Ishido, Shun;
Inada, Kento;
Kirino, Sakura;
Yamashita, Koji;
Nobusawa, Tsubasa;
Matsumoto, Hiroaki;
Kakegawa, Tatsuya;
Higuchi, Mayu;
Takaura, Kenta;
Tanaka, Shohei;
Maeyashiki, Chiaki;
Tamaki, Nobuharu;
Nakanishi, Hiroyuki;
Itakura, Jun

Publication type:

Article

Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 411, doi. 10.1007/s10637-021-01183-6

By:

Doshita, Kosei;
Kenmotsu, Hirotsugu;
Omori, Shota;
Tabuchi, Yuya;
Kawabata, Takanori;
Kodama, Hiroaki;
Nishioka, Naoya;
Miyawaki, Eriko;
Iida, Yuko;
Miyawaki, Taichi;
Mamesaya, Nobuaki;
Kobayashi, Haruki;
Ko, Ryo;
Wakuda, Kazushige;
Ono, Akira;
Naito, Tateaki;
Murakami, Haruyasu;
Mori, Keita;
Harada, Hideyuki;
Kaneko, Takeshi

Publication type:

Article

Efficacy and safety of mitoxantrone hydrochloride liposome injection in Chinese patients with advanced breast cancer: a randomized, open-label, active-controlled, single-center, phase II clinical trial.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 330, doi. 10.1007/s10637-021-01182-7

By:

Wang, Leiping;
Cao, Jun;
Li, Chunlei;
Wang, Xiaodong;
Zhao, Yannan;
Li, Ting;
Du, Yiqun;
Tao, Zhonghua;
Peng, Wenxia;
Wang, Biyun;
Zhang, Jian;
Zhang, Sheng;
Wang, Zhonghua;
Hu, Xichun

Publication type:

Article

Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 215, doi. 10.1007/s10637-021-01181-8

By:

Plangger, Adelina;
Rath, Barbara;
Hochmair, Maximilian;
Funovics, Martin;
Neumayer, Christoph;
Zeillinger, Robert;
Hamilton, Gerhard

Publication type:

Article

Phase Ia dose escalation study of OBP-801, a cyclic depsipeptide class I histone deacetylase inhibitor, in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 300, doi. 10.1007/s10637-021-01180-9

By:

Heath, Elisabeth I.;
Weise, Amy;
Vaishampayan, Ulka;
Danforth, Dailan;
Ungerleider, Richard S.;
Urata, Yasuo

Publication type:

Article

A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 308, doi. 10.1007/s10637-021-01179-2

By:

Huang, Meijuan;
Liu, Yongmei;
Yu, Min;
Li, Yanying;
Zhang, Yan;
Zhu, Jiang;
Li, Li;
Lu, You

Publication type:

Article

A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patients.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 314, doi. 10.1007/s10637-021-01178-3

By:

Yau, Thomas;
Cheng, Paul N. M.;
Chiu, Joanne;
Kwok, Gerry Gin Wai;
Leung, Roland;
Liu, Angela M.;
Cheung, Tan To;
Ng, Chi Tao

Publication type:

Article

Leukotriene B4 receptor 2 correlates with prognosis and immune infiltration in clear cell renal cell carcinoma.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 232, doi. 10.1007/s10637-021-01174-7

By:

Yuan, Xia;
He, Yi;
Luo, Chenhui;
Wang, Wei

Publication type:

Article

Rh-endostatin combined with chemotherapy in patients with advanced or recurrent mucosal melanoma: retrospective analysis of real-world data.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 453, doi. 10.1007/s10637-021-01172-9

By:

Zhang, Xiaowei;
Jin, Feng;
Jiang, Shiyu;
Cao, Jun;
Meng, Yanchun;
Xu, Yu;
ChunmengWang;
Chen, Yong;
Yang, Huijuan;
Kong, Yunyi;
Liu, Xin;
Luo, Zhiguo

Publication type:

Article

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non‐small cell lung cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 2, p. 265, doi. 10.1007/s10637-021-01121-6

By:

Ku, Bo Mi;
Heo, Jae Yeong;
Kim, Jinchul;
sun, Jong-Mu;
Lee, Se-Hoon;
Ahn, Jin Seok;
Park, Keunchil;
Ahn, Myung-Ju

Publication type:

Article